Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709138 | 0.80 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTABCC4TSHR | |
| SCHEMBL11602936 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL873301 | 0.78 | FAAH (0.51) | ALDH1A1LMNATSHRSMN1; SMN2EGLN1 | |
| SCHEMBL2497208 | 0.77 | ABCC4 (0.35) | ALDH1A1LMNAMAPTABCC4FAAH | |
| SCHEMBL28296563 | 0.77 | ABCC4 (0.35) | ALDH1A1LMNAMAPTABCC4FAAH | |
| SCHEMBL16046411 | 0.77 | TSHR (0.47) | ALDH1A1LMNATSHRHDAC3HDAC4 | |
| SCHEMBL7637914 | 0.76 | — | — | |
| SCHEMBL514725 | 0.76 | — | — | |
| SCHEMBL18863964 | 0.76 | TSHR (0.40) | ALDH1A1LMNAMAPTABCC4TSHR | |
| Water SCHEMBL11056984 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981820-B | Method for synthesizing quinoxaline-2-ketone under acidic condition | 上海彩迩文生化科技有限公司 | 2023-05-19 | — | — | CN | claimed |
| US-12295947-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2025-05-13 | — | — | US | disclosed |
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-110981820-B | Method for synthesizing quinoxaline-2-ketone under acidic condition | 上海彩迩文生化科技有限公司 | 2023-05-19 | — | — | CN | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-111018795-B | Method for synthesizing quinoxaline-3-ketone under alkaline condition | 上海彩迩文生化科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-110382466-B | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | 拉夸里亚创药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-11439633-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2022-09-13 | — | — | US | disclosed |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-9854803-B2 | Noxious arthropod control agent containing amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170215424-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| US-7217730-B2 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0420086-B1 | Pyrimidoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5256780-A | Serotonin antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5180728-A | Antagonists of 5-hydroxytryptamine | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-19 | — | — | US | disclosed |
| EP-0420086-A2 | Pyrimidoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | ALDH1A1 2351/4885LMNA 1991/4885MAPT 3367/4885 |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | ALDH1A1 495/4885LMNA 3740/4885MAPT 4759/4885 |
| US-20170215424-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | TRPA1, OPRM1, OPRL1 | ALDH1A1 2079/4885LMNA 3750/4885MAPT 3947/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | ALDH1A1 2351/4885LMNA 1991/4885MAPT 3367/4885 |
| US-11439633-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | ALDH1A1 2351/4885LMNA 1991/4885MAPT 3367/4885 |
| US-12295947-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | ALDH1A1 2351/4885LMNA 1991/4885MAPT 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.